This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - FactSet Research Systems (NYSE:FDS), Brinker International (NYSE:EAT)
华尔街分析师评级变动 - Barclays分析师Eddie Kim将Helmerich & Payne, Inc (HP)评级从Equal-Weight上调至Overweight,并将目标价从17美元上调至25美元,该股上周五收盘价为20.54美元 [3] - UBS分析师Alex Kramm将FactSet Research Systems Inc (FDS)评级从Neutral上调至Buy,但将目标价从480美元下调至425美元,该股上周五收盘价为289.15美元 [3] - BMO Capital分析师Kostas Biliouris将Sarepta Therapeutics, Inc (SRPT)评级从Market Perform上调至Outperform,并维持50美元的目标价,该股上周五收盘价为17.43美元 [3] - Evercore ISI Group分析师Daniel Markowitz将Repligen Corporation (RGEN)评级从In-Line上调至Outperform,并将目标价从130美元上调至155美元,该股上周五收盘价为122.30美元 [3] - Wells Fargo分析师Zachary Fadem将Brinker International, Inc (EAT)评级从Equal-Weight上调至Overweight,并将目标价从165美元上调至175美元,该股上周五收盘价为136.35美元 [3]